Literature DB >> 8369392

Power and sample size calculations for exact conditional tests with ordered categorical data.

J F Hilton1, C R Mehta.   

Abstract

We develop an algorithm for computing sample sizes, equal or unequal, for categorical data. We illustrate its use in the two-sample setting using the Wilcoxon rank-sum statistic, but the algorithm accommodates the entire class of linear rank statistics and can be extended to include nonlinear rank statistics as well. The sample size determinations can be based on either exact power or on a very precise Monte Carlo estimate of it. To reduce the computations further, power can be computed as a function of asymptotic critical values when the number of categories is not too small. For the Wilcoxon statistic we show that this approximation works well if there are more than five response categories.

Mesh:

Year:  1993        PMID: 8369392

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  6 in total

1.  Simulation study of power and sample size for repeated measures with multinomial outcomes: an application to sound direction identification experiments (SDIE).

Authors:  Dingfeng Jiang; Jacob J Oleson
Journal:  Stat Med       Date:  2011-07-12       Impact factor: 2.373

2.  Sample size/power calculations for repeated ordinal measurements in population pharmacodynamic experiments.

Authors:  Kayode Ogungbenro; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-12-05       Impact factor: 2.745

3.  Precise and accurate power of the rank-sum test for a continuous outcome.

Authors:  Katie R Mollan; Ilana M Trumble; Sarah A Reifeis; Orlando Ferrer; Camden P Bay; Pedro L Baldoni; Michael G Hudgens
Journal:  J Biopharm Stat       Date:  2020-03-04       Impact factor: 1.051

4.  Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis.

Authors:  A Alisi; G Bedogni; G Baviera; V Giorgio; E Porro; C Paris; P Giammaria; L Reali; F Anania; V Nobili
Journal:  Aliment Pharmacol Ther       Date:  2014-04-16       Impact factor: 8.171

5.  Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8.

Authors:  Ann E Kearns; Donald W Northfelt; Amylou C Dueck; Pamela J Atherton; Shaker R Dakhil; Kendrith M Rowland; Jyotsna Fuloria; Patrick J Flynn; Todor Dentchev; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2009-05-27       Impact factor: 3.603

6.  Optimal sample size planning for the Wilcoxon-Mann-Whitney test.

Authors:  Martin Happ; Arne C Bathke; Edgar Brunner
Journal:  Stat Med       Date:  2018-10-08       Impact factor: 2.373

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.